trending Market Intelligence /marketintelligence/en/news-insights/trending/e0k88qno2xwk-hqpvrs7dg2 content esgSubNav
In This List

Novo Nordisk hemophilia A therapy maintains potency at high temperatures

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Novo Nordisk hemophilia A therapy maintains potency at high temperatures

Novo Nordisk A/S said a long-term study showed that its hemophilia A treatment, called NovoEight, maintained its potency even after being stored at temperatures of 40 degrees C.

Hemophilia A patients often struggle with treatment storage issues, the Danish drugmaker said in a news release.

SNL Image

The storage conditions for NovoEight allow the therapy to be stored at temperatures of up to 40 degrees for three months.